Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations

Vaccine

Volumn 30, Issue 18, 2012, Pages 2831-2838

  Khatami, Ameneh ^a   Snape, Matthew D ^a   Davis, Elizabeth ^a   Layton, Helen ^a   John, Tessa ^a   Yu, Ly Mee ^a   Dull, Peter M ^b   Gill, Christopher J ^b   Odrjlin, Tatjana ^b   Dobson, Simon ^c   Halperin, Scott A ^d   Langley, Joanne M ^d   McNeil, Shelly A ^d   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Childhood; Immune response; Meningococcal; Persistence; Quadrivalent conjugate vaccine

Indexed keywords

BACTERIUM ANTIBODY; MENINGOCOCCUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANADA; CHILD; CHILD HEALTH CARE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; UNITED KINGDOM;

ADOLESCENT; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; CANADA; CHILD, PRESCHOOL; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOLOGIC MEMORY; INFANT; MALE; MENINGOCOCCAL VACCINES; MICROBIAL VIABILITY; NEISSERIA MENINGITIDIS; TIME FACTORS; VACCINES, CONJUGATE;

EID: 84859005838     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.046     Document Type: Article

References (45)

1. Rosenstein N.E., Perkins B.A., Stephens D.S., Popovic T., Hughes J.M. Meningococcal disease. N Engl J Med 2001, 344(May (18)):1378-1388.
2. Kvalsvig A.J., Unsworth D.J. The immunopathogenesis of meningococcal disease. J Clin Pathol 2003, 56(June (6)):417-422.
3. Cartwright K., Strang J., Reilly S., White D. Mortality in meningococcal disease. BMJ 1992, 304(January (6819)):116.
4. Healy C.M., Butler K.M., Smith E.O., Hensey O.P., Bate T., Moloney A.C., et al. Influence of serogroup on the presentation, course, and outcome of invasive meningococcal disease in children in the Republic of Ireland, 1995-2000. Clin Infect Dis 2002, 34(May (10)):1323-1330.
5. Armand J., Arminjon F., Mynard M.C., Lafaix C. Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: clinical and serological evaluation. J Biol Stand 1982, 10(October (4)):335-339.
6. Granoff D.M., Pollard A.J. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J 2007, 26(August (8)):716-722.
7. Kelly D.F., Snape M.D., Clutterbuck E.A., Green S., Snowden C., Diggle L., et al. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood 2006, 108(October (8)):2642-2647.
8. Snape M.D., Pollard A.J. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 2005, 5(January (1)):21-30.
9. Bilukha O.O., Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005, 54(May (RR-7):):1-21.
10. European Medicines Agency. Menveo: meningococcal group A, C, W135 and Y conjugate vaccine; 2010 [cited 2011 23 March 2011; EPAR summary for the public]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001095/WC500090148.pdf.
11. Health Canada Summary Basis of Decision (SBD): MENVEO™; 2010 [cited 2011 03/06/11]. Available from: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharma/sbd-smd/phase1-decision/drug-med/sbd_smd_2010_menveo_127046-eng.pdf.
12. Novartis. MENVEO® [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine]; 2011 [cited 2011 23 March 2011; Highlights of Prescribing Information]. Available from: https://www.novartisvaccinesdirect.com/PDF/Menveo_Full_Promotional_PI.pdf.
13. Reisinger K.S., Baxter R., Block S.L., Shah J., Bedell L., Dull P.M. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol 2009, 16(December (12)):1810-1815.
14. Perrett K.P., Snape M.D., Ford K.J., John T.M., Yu L.M., Langley J.M., et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J 2009, 28(March (3)):186-193.
15. Snape M.D., Perrett K.P., Ford K.J., John T.M., Pace D., Yu L.M., et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008, 299(January (2)):173-184.
16. Halperin S.A., Gupta A., Jeanfreau R., Klein N.P., Reisinger K., Walter E., et al. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. Vaccine 2010, 28(November (50)):7865-7872.
17. Gasparini R., Conversano M., Bona G., Gabutti G., Anemona A., Dull P.M., et al. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clin Vaccine Immunol 2010, 17(April (4)):537-544.
18. Novartis. Novartis receives FDA approval of Menveo®, a vaccine to prevent meningococcal disease; 2011 [cited 2011 23 March 2011; Media Release]. Available from: http://www.novartis.com/newsroom/media-releases/en/2010/1386845.shtml.
19. Borrow R., Andrews N., Findlow H., Waight P., Southern J., Crowley-Luke A., et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 2010, 17(January (1)):154-159.
20. Updated recommendations for use of meningococcal conjugate vaccines - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011, 60(January (3)):72-76.
21. European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe 2007. Surveillance report; 2010 [cited 2011 03/06/2011]. Available from: http://www.ecdc.europa.eu/en/publications/Publications/101011_SUR_Surveillance_of_invasive_bacterial_diseases_in_Europe_2007.pdf.
22. Gray S.J., Trotter C.L., Ramsay M.E., Guiver M., Fox A.J., Borrow R., et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006, 55(July (Pt. 7)):887-896.
23. Bettinger J.A., Scheifele D.W., Le Saux N., Halperin S.A., Vaudry W., Tsang R. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J 2009, 28(March (3)):220-224.
24. Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004, 364(July (9431)):365-367.
25. Campbell H., Andrews N., Borrow R., Trotter C., Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010, 17(May (5)):840-847.
26. Larrauri A., Cano R., Garcia M., Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005, 23(July (32)):4097-4100.
27. Perrett K.P., Winter A.P., Kibwana E., Jin C., John T.M., Yu L.M., et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis 2010, 50(June (12)):1601-1610.
28. Sakou I.I., Tzanakaki G., Tsolia M.N., Sioumala M., Barbouni A., Kyprianou M., et al. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine. Vaccine 2009, 27(July (33)):4408-4411.
29. Khatami A., Snape M.D., John T., Westcar S., Klinger C., Rollinson L., et al. Persistence of immunity following a booster dose of Haemophilus influenzae type B-meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial. Pediatr Infect Dis J 2011, 30(March (3)):197-202.
30. Snape M.D., Kelly D.F., Green B., Moxon E.R., Borrow R., Pollard A.J. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J 2005, 24(February (2)):128-131.
31. Snape M.D., Kelly D.F., Lewis S., Banner C., Kibwana L., Moore C.E., et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 2008, 336(June (7659)):1487-1491.
32. Snape M.D., Kelly D.F., Salt P., Green S., Snowden C., Diggle L., et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 2006, 43(December (11)):1387-1394.
33. McVernon J., MacLennan J., Pollard A.J., Oster P., Wakefield M.J., Danzig L., et al. Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years. Pediatr Infect Dis J 2003, 22(July (7)):659-661.
34. An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2009, 35(April (ACS-3)):1-40.
35. Burrage M., Robinson A., Borrow R., Andrews N., Southern J., Findlow J., et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun 2002, 70(September (9)):4946-4954.
36. Southern J., Crowley-Luke A., Borrow R., Andrews N., Miller E. Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine 2006, 24(January (2)):215-219.
37. Borrow R., Goldblatt D., Finn A., Southern J., Ashton L., Andrews N., et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom. Infect Immun 2003, 71(October (10)):5549-5555.
38. Hershey J.H., Hitchcock W. Epidemiology and meningococcal serogroup distribution in the United States. Clin Pediatr (Phila) 2010, 49(June (6)):519-524.
39. Rosenstein N.E., Perkins B.A., Stephens D.S., Lefkowitz L., Cartter M.L., Danila R., et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999, 180(December (6)):1894-1901.
40. Mayer L.W., Reeves M.W., Al-Hamdan N., Sacchi C.T., Taha M.K., Ajello G.W., et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electrophoretic type-37 complex. J Infect Dis 2002, 185(June (11)):1596-1605.
41. Aguilera J.F., Perrocheau A., Meffre C., Hahne S. Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis 2002, 8(August (8)):761-767.
42. Keyserling H., Papa T., Koranyi K., Ryall R., Bassily E., Bybel M.J., et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005, 159(October (10)):907-913.
43. Pichichero M., Papa T., Blatter M., Mitchell D., Kratz R., Sneed J., et al. Immune memory in children previously vaccinated with an experimental quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 2006, 25(November (11)):995-1000.
44. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(June (Suppl. 2)):B51-B63.
45. Department of Health. Immunisation against infectious disease - 'The Green Book'; Update Chapter 22:Meningococcal; 2011.